New drug aimed at slowing pancreatic cancer shows promise in early trial
NCT ID NCT07301229
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called HLX43 in 100 adults with advanced pancreatic cancer that has not responded to other treatments. The drug is designed to target and attack cancer cells while limiting harm to healthy cells. The goal is to see if it can shrink tumors or slow the disease, not to cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can zapping pancreatic tumors with heat before surgery boost Chemo's power?
- Can a radioactive tracer light up hidden tumors? a new trial aims to find out
- Breath of life: new test could sniff out gut cancers before they spread
- Scientists hunt for biomarkers to catch pancreatic cancer before it strikes
- New PET tracer aims to spot hidden cancer spread in the abdomen
- Experimental drug inavolisib targets Hard-to-Treat pancreatic cancer